Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: NH NONMETROPOLITAN AREA — September 2026
Lonza's build-out meets NH's shrinking entry-level talent pool.
Lonza plans 300-400 new Portsmouth roles by 2027 even as statewide ongoing unemployment claims run 23% above two years ago and Clinical Research Associate pay climbs to $113,121, well above the $90,956 national median.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- NH unemployment rate: 2.8% — 5th lowest nationally, down from 3.2% in 2025
- Lonza Portsmouth headcount growth: +300-400 roles — By end-2027, from 2,400 current employees
- NH ongoing unemployment claims: +23% — vs same period two years prior, despite low headline rate
- Core life sciences employment growth: 24% (2019-2025) — vs 4% statewide private-sector growth overall
Key takeaways
Regulatory Affairs pay is falling locally while scarcity rises nationally.
Metro Regulatory Affairs Specialist advertised pay dropped significantly to $90,389, roughly $14,000 below the national median, even as VP-level regulatory talent nationally commands $320K-$580K amid acute global scarcity. The gap may suggest nonmetro employers are pricing junior-to-mid regulatory roles out of step with a market where regulatory expertise is accelerating in strategic value.
Clinical research pay is outrunning the national market.
Clinical Research Associate advertised pay in the metro reached $113,121, roughly $22,000 above the national median, a significant premium for a nonmetropolitan labor pool. This is consistent with thin local supply forcing employers to bid aggressively rather than rely on relocation incentives alone.
Manufacturing build-out is colliding with a shrinking entry-level pipeline.
Lonza's planned addition of 300-400 Portsmouth roles arrives as NH's 20-34 age cohort shrinks in the labor force and statewide ongoing unemployment claims run 23% above two years ago. Sustained manufacturing hiring may increasingly depend on retraining older workers or recruiting from outside commuting range rather than traditional entry-level channels.
Validation Engineer softness may reflect outsourcing, not disinterest.
Metro Validation Engineer advertised pay fell to $99,201 even as the national figure rose to $108,377, a divergence that could reflect CDMO/CRO partners absorbing validation workloads rather than employers building internal capacity. Worth testing against build-vs-outsource plans before assuming reduced demand.
Median advertised pay by role — NH NONMETROPOLITAN AREA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist | $100,092 | $117,607 | $134,363 | Significant increase | $131,354 |
| Clinical Research Associate | $104,980 | $113,121 | $114,519 | Significant increase | $90,956 |
| Lab Technician | $42,380 | $52,416 | $57,070 | Moderate increase | $47,402 |
| Regulatory Affairs Specialist | $85,708 | $90,389 | $105,125 | Significant decline | $104,000 |
| Clinical Data Manager * | $96,400 | $112,177 | $119,196 | Moderate decline | $123,031 |
| Biostatistician | $156,466 | $156,466 | $159,623 | Moderate increase | $133,322 |
| Validation Engineer | $88,174 | $99,201 | $100,145 | Moderate decline | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
New Hampshire's nonmetropolitan counties are riding a tight statewide labor market, with unemployment at 2.8% and nonfarm employment up 1.1% year-to-date, but wage growth is losing a 1.6% purchasing-power race against inflation. Core life sciences employment statewide has grown 24% since 2019 against just 4% private-sector growth overall, concentrating demand in manufacturing and quality roles that rural and small-town labor pools were not built to supply.
What it means
Lonza's Portsmouth expansion — adding 300-400 roles by 2027 across manufacturing, quality, and support — signals that anchor employers are committing to in-state build-out even as statewide wage growth lags inflation, intensifying competition for technicians and engineers in a nonmetro labor pool already thinned by 20-34 year-old outmigration. UNH researchers frame this as a talent alignment problem, not a shortage, meaning headcount plans built around traditional biomedical science hiring pipelines will underperform against the actual mix of manufacturing and supply-chain skills needed. Consider evaluating whether current technician and engineer job architectures reflect the skills Lonza-scale manufacturing actually requires, rather than legacy R&D-centric role definitions.
Looking ahead
Expected: Lonza's phased hiring toward 300-400 added Portsmouth roles through 2027 should start showing up in local job postings volume over the next two quarters. Track whether advertised pay for manufacturing and quality roles moves further above the current $20.26/hour statewide biotech manufacturing average.
Emerging pressure point: Ongoing unemployment claims statewide are up 23% versus two years prior even as headline unemployment sits at 2.8%, a divergence worth monitoring for signs of mismatch between displaced workers' skills and life sciences openings. NH-LIFT workforce initiatives remain 18-24 months from measurable hiring impact.
Worth watching: National biopharma layoffs (BioMarin, Bristol Myers) are concentrated in consolidation functions while 64% of surveyed organizations keep recruiting, a pattern that could push displaced specialized talent toward New England manufacturing hubs including NH. Watch whether Portsmouth-area postings begin drawing applicants from outside the state.
Potential inflection point: Regulatory Affairs Specialist advertised pay has fallen significantly locally while national VP-level regulatory compensation keeps climbing on EU MDR and faster FDA pathway pressure. A continued local-national divergence may force a near-term compensation correction to retain scarce regulatory talent.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.